Abivax SA American Depositary Shares
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as … Read more
Abivax SA American Depositary Shares - Asset Resilience Ratio
Abivax SA American Depositary Shares (ABVX) has an Asset Resilience Ratio of 0.07% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2024)
This chart shows how Abivax SA American Depositary Shares's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Abivax SA American Depositary Shares's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $136.00K | 0.07% |
| Total Liquid Assets | $136.00K | 0.07% |
Asset Resilience Insights
- Limited Liquidity: Abivax SA American Depositary Shares maintains only 0.07% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Abivax SA American Depositary Shares Industry Peers by Asset Resilience Ratio
Compare Abivax SA American Depositary Shares's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Abivax SA American Depositary Shares (2013–2024)
The table below shows the annual Asset Resilience Ratio data for Abivax SA American Depositary Shares.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.07% | $136.00K | $205.23 Million | -2.70pp |
| 2023-12-31 | 2.77% | $9.05 Million | $327.06 Million | +2.76pp |
| 2022-12-31 | 0.01% | $6.00K | $75.54 Million | +0.00pp |
| 2021-12-31 | 0.01% | $6.00K | $109.23 Million | 0.00pp |
| 2020-12-31 | 0.01% | $6.00K | $71.30 Million | 0.00pp |
| 2019-12-31 | 0.01% | $6.00K | $51.73 Million | -9.25pp |
| 2018-12-31 | 9.26% | $5.01 Million | $54.05 Million | -18.89pp |
| 2017-12-31 | 28.15% | $15.15 Million | $53.81 Million | +3.32pp |
| 2016-12-31 | 24.84% | $15.05 Million | $60.60 Million | +6.48pp |
| 2015-12-31 | 18.36% | $14.00 Million | $76.27 Million | +13.87pp |
| 2014-12-31 | 4.49% | $1.70 Million | $37.97 Million | +3.45pp |
| 2013-12-31 | 1.04% | $400.00K | $38.46 Million | -- |